IRAK

亜型選択性的な製品

IRAK1 IRAK4

IRAK製品

All (16)
IRAK阻害剤 (16)
新製品

製品コード	製品名称	製品説明	文献中Selleckの製品使用例
S8663	Takinib	Takinib is a potent and selective TAK1 inhibitor with an IC50 of 9.5 nM, more than 1.5 log more potent than the second and third ranked targets, IRAK4 (120 nM) and IRAK1 (390 nM), respectively. Takinib induces apoptosis.	Gut Microbes, 2024, 16(1):2402543 Nat Commun, 2023, 14(1):143 Front Immunol, 2023, 14:1266315
S8531	Zimlovisertib (PF-06650833)	Zimlovisertib (PF-06650833) is a potent, selective inhibitor of IRAK4 with an IC50 of 0.2 nM.	J Gen Virol, 2023, 104(5)001858 Nat Commun, 2022, 13(1):4229 Nat Commun, 2022, 13(1):4229
S3924	Ginsenoside Rb1	Ginsenoside Rb1 (Gypenoside Ⅲ) is a protopanaxadiol that has diverse in vitro and in vivo effects, including neuroprotective, anti-inflammatory, and anti-obesity actions. Ginsenoside Rb1, a main constituent of the root of Panax ginseng, inhibits Na+, K+-ATPase activity with IC50 of 6.3±1.0 μM. Ginsenoside also inhibits IRAK-1 activation and phosphorylation of NF-κB p65. Ginsenoside Rb1 reduces the expressions of TLR3, TLR4 and TRAF-6, and down-regulates the levels of TNF-α, IFN-β and iNOS.	J Biol Chem, 2024, 300(8):107542 J Ethnopharmacol, 2021, S0378-8741(21)00169-0 J Biol Chem, 2021, S0021-9258(21)00790-0
S0008	IRAK4-IN-1	IRAK4-IN-1 (Compound 23) is a highly selective inhibitor of IRAK4 with an IC50 of 7 nM.	Syst Biol Reprod Med, 2022, 1-15 Histochem Cell Biol, 2021, 156(3):227-237
S8562	IRAK4-IN-2	IRAK4-IN-2 is a reversible kinase inhibitor that modulates IRAK4 function in both the toll-like receptor (TLR) and interleukin 1 receptor (IL-1R) signaling cascades.	Cancer Lett, 2021, 503:75-90 Cancer Lett, 2021, 503:75-90
S6598	IRAK-1-4 Inhibitor I	IRAK-1-4 Inhibitor I is an inhibitor of interleukin-1 receptor associated kinase (IRAK) with IC50 values of 0.3 μM and 0.2 μM for IRAK-1 and IRAK-4, respectively. It displays IC50 values >10 µM in a panel of 27 other kinases tested.	Nat Commun, 2022, 13(1):6226 Nat Commun, 2022, 13(1):6226
S9779	Emavusertib (CA-4948)	Emavusertib (CA-4948) is a potent and orally bioavailable inhibitor of interleukin-1 receptor-associated kinase 4/FMS-like Tyrosine Kinase 3 (IRAK4/FLT3) with anti-tumor activity.	Arthritis Rheumatol, 2021, 10.1002/art.42043
S3607	Sarsasapogenin	Sarsasapogenin (SAR, Parigenin) is a steroidal sapogenin. It can provoke the generation of reactive oxygen species and activate unfolded protein response (UPR) signaling pathways. SAR potently inhibits NF-κB and MAPK activation, as well as IRAK1, TAK1, and IκBα phosphorylation in LPS-stimulated macrophages.	J Exp Clin Cancer Res, 2022, 41(1):174
E1655^New	KT 474	KT-474 (SAR444656) is a selective small-molecule degrader of IRAK4 in development for the treatment of TLR/IL-1R–driven autoimmune diseases. KT-474 potently downregulates R848 (TLR7/8) and lipopolysaccharide (LPS)-induced IL-6 and IL-8 production in peripheral blood mononuclear cells (PBMCs).
E2837	Zabedosertib	Zabedosertib (BAY 1834845) is a IRAK4 inhibitor with immunomodulatory potential, which is a protein kinase involved in signaling innate immune responses from Toll-like receptors.
S0775	IRAK4-IN-4	IRAK4-IN-4 (compound 15) is an inhibitor of interleukin-1 receptor–associated kinase 4 (IRAK4) and cyclic GMP-AMP synthase (cGAS) with IC50 of 2.8 nM and 2.1 nM, respectively.
S9780	JH-X-119-01	JH-X-119-01 is a highly potent and selective covalent inhibitor of IRAK1 with IC50 of 9 nM.	J Gen Virol, 2023, 104(5)001858
S9701	HS-243	HS-243 is a highly potent interleukin-1 receptor-associated kinase (IRAK) inhibitor with IC50 of 24 nM, 20 nM and 0.5 μM for IRAK-1, IRAK-4 and TAK1, respectively.
S2039	IRAK inhibitor 6	IRAK inhibitor 6 is a selective Interleukin-1 receptor-associated kinase 4(IRAK4) inhibitor with IC50 of 0.16 μM.
E0533	IRAK-4 protein kinase inhibitor 2	IRAK-4 protein kinase inhibitor 2 is a potent inhibitor of interleukin-1 (IL-1) receptor-associated kinase-4 (IRAK-4), with an IC50 of 4 μM.
E2647	AZ1495	AZ1495 is an oral active inhibitor of Interleukin-1 receptor associated kinase 4 (IRAK4), with IC50 values of 5 nM and 23 nM for IRAK4 and IRAK1, respectively.
S8663	Takinib	Takinib is a potent and selective TAK1 inhibitor with an IC50 of 9.5 nM, more than 1.5 log more potent than the second and third ranked targets, IRAK4 (120 nM) and IRAK1 (390 nM), respectively. Takinib induces apoptosis.	Gut Microbes, 2024, 16(1):2402543 Nat Commun, 2023, 14(1):143 Front Immunol, 2023, 14:1266315
S8531	Zimlovisertib (PF-06650833)	Zimlovisertib (PF-06650833) is a potent, selective inhibitor of IRAK4 with an IC50 of 0.2 nM.	J Gen Virol, 2023, 104(5)001858 Nat Commun, 2022, 13(1):4229 Nat Commun, 2022, 13(1):4229
S3924	Ginsenoside Rb1	Ginsenoside Rb1 (Gypenoside Ⅲ) is a protopanaxadiol that has diverse in vitro and in vivo effects, including neuroprotective, anti-inflammatory, and anti-obesity actions. Ginsenoside Rb1, a main constituent of the root of Panax ginseng, inhibits Na+, K+-ATPase activity with IC50 of 6.3±1.0 μM. Ginsenoside also inhibits IRAK-1 activation and phosphorylation of NF-κB p65. Ginsenoside Rb1 reduces the expressions of TLR3, TLR4 and TRAF-6, and down-regulates the levels of TNF-α, IFN-β and iNOS.	J Biol Chem, 2024, 300(8):107542 J Ethnopharmacol, 2021, S0378-8741(21)00169-0 J Biol Chem, 2021, S0021-9258(21)00790-0
S0008	IRAK4-IN-1	IRAK4-IN-1 (Compound 23) is a highly selective inhibitor of IRAK4 with an IC50 of 7 nM.	Syst Biol Reprod Med, 2022, 1-15 Histochem Cell Biol, 2021, 156(3):227-237
S8562	IRAK4-IN-2	IRAK4-IN-2 is a reversible kinase inhibitor that modulates IRAK4 function in both the toll-like receptor (TLR) and interleukin 1 receptor (IL-1R) signaling cascades.	Cancer Lett, 2021, 503:75-90 Cancer Lett, 2021, 503:75-90
S6598	IRAK-1-4 Inhibitor I	IRAK-1-4 Inhibitor I is an inhibitor of interleukin-1 receptor associated kinase (IRAK) with IC50 values of 0.3 μM and 0.2 μM for IRAK-1 and IRAK-4, respectively. It displays IC50 values >10 µM in a panel of 27 other kinases tested.	Nat Commun, 2022, 13(1):6226 Nat Commun, 2022, 13(1):6226
S9779	Emavusertib (CA-4948)	Emavusertib (CA-4948) is a potent and orally bioavailable inhibitor of interleukin-1 receptor-associated kinase 4/FMS-like Tyrosine Kinase 3 (IRAK4/FLT3) with anti-tumor activity.	Arthritis Rheumatol, 2021, 10.1002/art.42043
S3607	Sarsasapogenin	Sarsasapogenin (SAR, Parigenin) is a steroidal sapogenin. It can provoke the generation of reactive oxygen species and activate unfolded protein response (UPR) signaling pathways. SAR potently inhibits NF-κB and MAPK activation, as well as IRAK1, TAK1, and IκBα phosphorylation in LPS-stimulated macrophages.	J Exp Clin Cancer Res, 2022, 41(1):174
E1655^New	KT 474	KT-474 (SAR444656) is a selective small-molecule degrader of IRAK4 in development for the treatment of TLR/IL-1R–driven autoimmune diseases. KT-474 potently downregulates R848 (TLR7/8) and lipopolysaccharide (LPS)-induced IL-6 and IL-8 production in peripheral blood mononuclear cells (PBMCs).
E2837	Zabedosertib	Zabedosertib (BAY 1834845) is a IRAK4 inhibitor with immunomodulatory potential, which is a protein kinase involved in signaling innate immune responses from Toll-like receptors.
S0775	IRAK4-IN-4	IRAK4-IN-4 (compound 15) is an inhibitor of interleukin-1 receptor–associated kinase 4 (IRAK4) and cyclic GMP-AMP synthase (cGAS) with IC50 of 2.8 nM and 2.1 nM, respectively.
S9780	JH-X-119-01	JH-X-119-01 is a highly potent and selective covalent inhibitor of IRAK1 with IC50 of 9 nM.	J Gen Virol, 2023, 104(5)001858
S9701	HS-243	HS-243 is a highly potent interleukin-1 receptor-associated kinase (IRAK) inhibitor with IC50 of 24 nM, 20 nM and 0.5 μM for IRAK-1, IRAK-4 and TAK1, respectively.
S2039	IRAK inhibitor 6	IRAK inhibitor 6 is a selective Interleukin-1 receptor-associated kinase 4(IRAK4) inhibitor with IC50 of 0.16 μM.
E0533	IRAK-4 protein kinase inhibitor 2	IRAK-4 protein kinase inhibitor 2 is a potent inhibitor of interleukin-1 (IL-1) receptor-associated kinase-4 (IRAK-4), with an IC50 of 4 μM.
E2647	AZ1495	AZ1495 is an oral active inhibitor of Interleukin-1 receptor associated kinase 4 (IRAK4), with IC50 values of 5 nM and 23 nM for IRAK4 and IRAK1, respectively.
E1655^New	KT 474	KT-474 (SAR444656) is a selective small-molecule degrader of IRAK4 in development for the treatment of TLR/IL-1R–driven autoimmune diseases. KT-474 potently downregulates R848 (TLR7/8) and lipopolysaccharide (LPS)-induced IL-6 and IL-8 production in peripheral blood mononuclear cells (PBMCs).

IRAK阻害剤の選択性比較